CRO market to recover, using 'hybrid trials,' with revenue hitting $64B by 2024: report

The contract research market has been squeezed hard by COVID-19, but it should still grow to $63.83 billion by 2024.

This is according to new analysis out by Frost & Sullivan, which also says part of this recovery will be based on new ways of doing trials, including hybrid clinical trials that are using safety-focused, direct-to-consumer logistical solutions, which “are taking center stage, ensuring research continuity.”